| Title : Diabetic individuals with COVID-19 exhibit reduced efficacy of gliptins in inhibiting dipeptidyl peptidase 4 (DPP4). A suggested explanation for increased COVID-19 susceptibility in patients with type 2 diabetes mellitus (T2DM) - Mora-Rodriguez_2023_Life.Sci_336_122292 |
| Author(s) : Mora-Rodriguez JM , Sanchez BG , Bort A , Diaz-Yuste A , Ballester-Gonzalez R , Arrieta F , Sebastian-Martin A , Diaz-Laviada I |
| Ref : Life Sciences , 336 :122292 , 2023 |
| Abstract : Mora-Rodriguez_2023_Life.Sci_336_122292 |
| ESTHER : Mora-Rodriguez_2023_Life.Sci_336_122292 |
| PubMedSearch : Mora-Rodriguez_2023_Life.Sci_336_122292 |
| PubMedID: 38030058 |
Mora-Rodriguez JM, Sanchez BG, Bort A, Diaz-Yuste A, Ballester-Gonzalez R, Arrieta F, Sebastian-Martin A, Diaz-Laviada I (2023)
Diabetic individuals with COVID-19 exhibit reduced efficacy of gliptins in inhibiting dipeptidyl peptidase 4 (DPP4). A suggested explanation for increased COVID-19 susceptibility in patients with type 2 diabetes mellitus (T2DM)
Life Sciences
336 :122292
Mora-Rodriguez JM, Sanchez BG, Bort A, Diaz-Yuste A, Ballester-Gonzalez R, Arrieta F, Sebastian-Martin A, Diaz-Laviada I (2023)
Life Sciences
336 :122292